Study of Infigratinib in Children With Achondroplasia
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to
evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor
receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in children 3 to 11 years of age
with Achondroplasia (ACH) who previously participated in the PROPEL study (Protocol
QBGJ398-001) for at least 6 months. The study includes dose escalation with extended
treatment, and dose expansion.